Table 2.
Knockout/Knockdown of Specific Nox Isoforms in Experimental Ischemic Stroke
| Genotype | Ischemic period [min] | Assessment of lesion volume after MCAO [h] | Stain | KO protective? | Ref. |
|---|---|---|---|---|---|
| siRNA Nox1 (rat) | 90 | 24 | N.D. | Yes | (35) |
| Nox1y/− | 30 | 24 | Thionin | No | (86) |
| 60 | 24 | TTC | No | (96) | |
| 60 | 24 | TTC | Yes | (89) | |
| 120 | 24 | TTC | No | (89) | |
| Permanent | 24 | TTC | No | (89) | |
| Nox2y/− | 25 | 72 | CV | Yes | (97) |
| 30 | 24 | Thionin | Yes | (44) | |
| 60 | 24 | TTC | No | (96) | |
| 75 | 24 | TTC | Yes | (33) | |
| 120 | 24 | TTC | Yes | (172) | |
| 120 | 24 | TTC | Yes | (90) | |
| 120 | 24 | HE | Yes | (163) | |
| Nox4−/− | 60 | 24 | TTC | Yes | (96) |
| Permanent | 24 | TTC | Yes | (96) |
MCAO, middle cerebral artery occlusion; KO, knockout; CV, cresyl violet; HE, hematoxylin and eosin; N.D., not determined; TTC, 2,3,5-triphenyl-tetrazolium chloride.